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OBJECTIVES This study was designed to determine whether admission to a Canadian hospital with on-site
revascularization (invasive hospital) affected revascularization choice, timing, and outcome
compared with community (non-invasive) hospitals.
BACKGROUND Health care systems in Canada are characterized by relative restraint in diffusion of tertiary
cardiovascular services, with capacity for revascularization procedures concentrated in large
regional referral centers.
METHODS We used linked administrative data and a clinical registry to follow-up 15,166 Ontario
patients who underwent revascularization within the year after their index acute myocardial
infarction (MI). Outcomes included recurrent urgent cardiac hospitalization, hospital
bed-days, and death within the same year after the index admission. We adjusted for age,
gender, socioeconomic status, illness severity, attending physician specialty, and academic
hospital affiliation.
RESULTS After adjusting for baseline factors, patients admitted to invasive hospitals were more likely
to receive angioplasty than bypass surgery (adjusted odds ratio: 1.85; 95% confidence interval:
1.68 to 2.04, p  0.001). The converse pattern was seen for patients admitted to community
hospitals. Median revascularization waiting times were significantly shorter at invasive
hospitals (12 vs. 48 days, p 0.001). Patients admitted to invasive hospitals had fewer cardiac
re-admissions (41.5 vs. 68.9 events per 100 patients, p  0.001) before their first
revascularization and consumed fewer hospital bed-days (379 vs. 517 per 100 patients, p 
0.001). There were no differences in outcomes beyond revascularization.
CONCLUSIONS Outcome advantages associated with timely post-MI revascularization highlight the impor-
tance of organizing revascularization referral networks and facilitating access to revascular-
ization for patients with acute coronary syndromes admitted to community hospitals in
Canada. (J Am Coll Cardiol 2003;42:410–9) © 2003 by the American College of
Cardiology Foundation
Patients admitted to hospitals with on-site revascularization
capability undergo coronary artery bypass graft surgery or
percutaneous transluminal coronary angioplasty earlier and
more frequently than those admitted to community hospi-
tals (1–4). Accumulating evidence suggests that delays in
revascularization are undesirable in eligible patients (5–9).
This poses challenges for the optimal organization of
cardiac care in universal health systems where procedural
capacity tends to be concentrated in regional referral centers.
See page 420
We sought to confirm the extent of differences in timing
of intervention after myocardial infarction (MI) between
hospitals with (invasive) and without (non-invasive) revas-
cularization. We hypothesized that any differences in timing
might be attributable in part to factors such as a higher
proportion of attending cardiologists and early use of
angioplasty in invasive hospitals (10). We also hypothesized
that differences in procedural waiting times could be asso-
ciated with a higher rate of complications among patients
awaiting revascularization (7,8,11).
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METHODS
System context. The Canadian health insurance system
provides universal coverage for basic in-hospital care, with-
out charges at point of service or a parallel private system. In
Ontario, funding for angioplasty and bypass surgery is based
on population-based target rates (with benchmark per capita
rates for bypass and angioplasty each set at 100 per 100,000
adults during the study period). Population-based capacity
for revascularization in Ontario is markedly lower than in the
U.S. and similar to many European nations, albeit higher than
the U.K., Spain, and Portugal (12). Such services are region-
alized to selected tertiary cardiac centers with the expectation
that populations residing within surrounding catchment areas
are equitably serviced. During the study period, nine of 201
acute-care hospitals (invasive centers) throughout Ontario
offered on-site angioplasty and bypass facilities.
Data sources. The Ontario Myocardial Infarction Data-
base (OMID) project links all of Ontario’s major health care
administrative databases with follow-up tracking of out-of-
hospital mortality over time, regardless of site of death.
Complete details regarding the construction of the OMID
cohort, including eligibility criteria and coding accuracy,
have been published elsewhere (13). For this study, the
cohort was also linked to the Cardiac Care Network of
Ontario registry as a source of supplemental clinical and
angiographic information for patients who underwent cor-
onary bypass surgery in Ontario. The study was approved by
the Research Ethics Board of the Sunnybrook and Wom-
en’s College Health Sciences Centre.
Cohort. The cohort consisted of any patient admitted to
hospital with a most responsible diagnosis of acute myocar-
dial infarction (AMI) (International Classification of
Diseases-9th Revision [ICD-9] code 410) in Ontario be-
tween April 1, 1994, and March 31, 1998, inclusive, who
received myocardial revascularization procedures within the
first 12 months after their infarct. Each patient was repre-
sented only once in the cohort. Revascularization proce-
dures (as defined as the first of either bypass surgery or
angioplasty) were assessed until one year after MI in order
to allow for appropriate post-MI risk stratification and
waiting times (14,15). We excluded patients (4.5% of the
cohort) admitted to institutions with on-site angiography-
only facilities and those (3.5%) for whom no information
regarding the attending physician was available.
To preclude confusion of the results by differential use of
primary or salvage angioplasty as a primary modality for
treatment of AMI, we excluded all patients receiving revas-
cularization on the same day as their AMI admission (Fig.
1). A re-analysis of our data with the inclusion of such
patients did not significantly alter our results.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AMI  acute myocardial infarction
CI  confidence interval
ICD-9  International Classification of Diseases-
9th Revision
MI  myocardial infarction
OMID  Ontario Myocardial Infarction Database
OR  odds ratio
RR  relative risk
Figure 1. Study flow chart. AMI  acute myocardial infarction.
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Hospital, physician, and patient characteristics. Based
on our a priori hypotheses, we focused on the presence or
absence of on-site revascularization capacity at the admit-
ting hospital. Patients were categorized according to their
initial admitting hospital, regardless of downstream trans-
fers. Among 12,968 patients initially admitted to non-
invasive hospitals, 5,208 patients (40.2%) were transferred
to other institutions during the index hospital stay. Each
patient’s initial length of hospital stay during the index AMI
admission reflected the total number of days spent at both
the transferring and receiving hospitals.
Baseline patient characteristics including age, gender, and
disease severity were obtained from discharge abstracts of
the index AMI admission. Socioeconomic status was in-
ferred from neighborhood income profiles as recorded in
official 1996 Canadian census data (16). To control for
variations in severity of illness upon admission, we used
variables obtained from the Ontario AMI mortality predic-
tion rule. The rule shows an area under the receiver-
operating curve of 0.77 in validation data sets (13).
Outcomes. We examined procedural waiting times and
adverse outcomes (urgent or emergent cardiac re-
admissions, mortality, and hospital bed-days) at one year
after MI. Because the exact date of referrals for procedures
could not be determined from administrative data, the
number of days between admission and initial revascular-
ization procedure served as a waiting time surrogate
(1,16,17).
We used urgent/emergent cardiac re-admissions as our
primary measure of complications attributable to delayed
revascularization. We excluded all elective hospitalizations.
Urgent cardiac re-admissions were defined to include a
primary diagnosis of recurrent AMI (ICD-9 code 410),
angina (ICD-9 codes 411, 413), or congestive heart failure
(ICD-9 code 428). About 97% of such re-admission codes
are accompanied by a concomitant emergency room physi-
cian assessment (1), thus these codes do reflect urgent
clinical need.
Because we examined only patients who survived to and
after revascularization, the study could not assess differential
mortality in the queue arising from delayed intervention.
Hence, mortality was examined on an exploratory basis,
focusing specifically on survival beyond revascularization.
To ensure similar inter-group exposure periods to the risks
of death after procedures, our mortality analysis was con-
fined to those patients who underwent their revasculariza-
tion during the index AMI hospitalization. We hypothe-
sized that mortality would be similar in the two groups
(1,18).
Last, we determined the number of hospital bed-days
attributable to recurrent cardiac admissions as well as the
cumulative number of hospital bed-days (for any reason) for
each patient in our cohort.
Analysis. Categorical differences in patient characteristics
were compared using chi-square tests and continuous dif-
ferences compared with a t test. We adjusted for patient
factors (sociodemographic characteristics and illness severi-
ty), physician factors (attending physician specialty), and
hospital factors (on-site revascularization, geographic prox-
imity to tertiary centers, academic affiliation, and hospital
size) in multivariate analyses.
Procedural waiting times were examined using Poisson
regression techniques. Time to first cardiac re-admission
was assessed using Cox proportional hazards for: 1) the
interval between discharge from the index admission and
the first downstream revascularization procedure; and 2) the
interval between the revascularization procedure (or hospital
discharge if revascularization was undertaken during the
index AMI admission) and the end of follow-up (i.e., one
year after the index AMI). When assessing the one-year risk
of cardiac re-admissions beyond intervention, patients were
censored at the time of death, if mortality occurred before
the first year after the index AMI. All multivariate analyses
were constructed in a similar fashion using backward step-
wise regression techniques (forcing age, gender, and illness
severity into the model). We also undertook a pre-specified
subgroup analysis (for patients of age 65 years and older) to
determine whether differences in the use of evidence-based
therapies (defined as aspirin, beta-blockers, angiotensin-
converting enzyme [ACE] inhibitors, HMG-CoA reduc-
tase inhibitors, and the withholding of calcium-channel
blockers) had any impact on inter-hospital variations in the
risk of recurrent cardiac admissions.
To confirm the robustness of our results, our analyses
were repeated using hierarchical logistic and Poisson regres-
sion (1,19). The results were similar with different statistical
techniques. Consistent with our preference for modeling
re-admission and mortality outcomes as functional hazards
rather than as binary outcome variables, we present only the
findings of our traditional Cox proportional hazard and
Poisson regression models because of space limitations.
Statistical significance was defined as p  0.05 for all
analyses. Multilevel analyses were implemented using HLM
version 5. SAS statistical software (version 8.2, SAS Insti-
tute Inc., Cary, North Carolina) was used for all remaining
statistical analyses.
RESULTS
Table 1 illustrates that patients admitted to invasive insti-
tutions with on-site revascularization services tended to
have higher cardiac severity and greater co-morbidities than
those admitted to non-invasive hospitals. Although pre-
scription rates among the elderly for most evidence-based
pharmacotherapies were similar between hospital groups,
elderly patients from non-invasive hospitals were signifi-
cantly more likely to be discharged while receiving calcium-
channel blockers and nitrates than those from invasive
institutions. Table 2 illustrates the breakdown of sociode-
mographic and clinical characteristics for patients receiving
surgical (compared with percutaneous) revascularization at
either type of institution. Patients undergoing bypass sur-
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gery differed systematically from those undergoing angio-
plasty, regardless of whether the initial site of admission was
an invasive or non-invasive hospital.
Utilization rates of revascularization. Compared with
those in non-invasive hospitals, patients admitted to inva-
sive hospitals were more likely to receive angioplasty (59.8%
vs. 46.9%, p  0.001), with mirror differences in bypass
surgery use after MI. The differential use of angioplasty at
invasive compared with non-invasive hospitals persisted
after adjusting for patient factors (adjusted odds ratio [OR]:
1.85; 95% confidence interval [CI]: 1.68 to 2.04, p 0.001)
and specialty characteristics of the attending physician
(adjusted OR: 1.75; 95% CI: 1.59 to 1.94, p  0.001).
Waiting times for revascularization. Median waiting
times for revascularization were shorter at invasive hospitals
(Table 3; 12 days vs. 48 days, p 0.001). After adjusting for
Table 1. Baseline characteristics of the AMI Patients in Ontario Referred for Revascularization
Procedures Between 1994 and 1998, According to Invasive and Non-Invasive Hospitals*
Variables
Invasive
Hospitals
(N  2,198)
Non-Invasive
Hospitals
(N  12,968) p Value
Patient factors
Demographic
Age, yrs 61.3 60.5 0.002
Male gender, % 73.8 73.9 0.94
Average household income, $† 21,762 21,049  0.001
Cardiogenic shock, % 0.82 0.54 0.11
Clinical status at admission
Congestive heart failure, % 13.7 10.1  0.001
Pulmonary edema, % 0.45 0.75 0.13
Cardiac dysrhythmia, % 15.0 8.7  0.001
Malignancy, % 0.73 0.76 0.86
Diabetes with complications, % 2.1 1.4 0.03
Stroke, % 1.64 1.44 0.48
Acute renal insufficiency, % 0.82 0.27  0.001
Chronic renal insufficiency, % 3.4 0.83  0.001
Canadian Cardiovascular Society class‡
I–III, %§ 28.3 36.5  0.001
IVA, % 23.4 21.6
IVB, % 31.5 26.9
IVC, % 16.9 14.9
Coronary anatomy‡
Isolated left main disease, % 15.8 14.2 0.19
High risk anatomy, % 82.0 78.2 0.01
One or two vessel disease, %¶ 18.0 21.8
Left ventricular dysfunction‡
Calculated urgency‡
Moderate or severe, % 40.1 33.4  0.001
Mild or none, % 60.0 66.6
Recommended maximum waiting
times (median days)
26.8 (13) 29.3 (13) 0.04
Proportion of bypass surgery within
recommended maximum waiting
times, %
59.2 53.1  0.001
Length of hospital stay#
Mean number of days (median) 11.4 (9) 12.4 (9)  0.001
Medication use**
Aspirin, % 69.5 68.4 0.51
Beta blockers, % 72.8 69.9 0.07
Calcium channel blockers, % 30.3 38.1  0.001
HMG-CoA reductase inhibitors, % 31.0 33.0 0.25
ACE inhibitors, % 49.9 47.2 0.12
Nitrates, % 67.8 73.1 0.001
*Invasive hospitals hospitals with on-site angiography revascularization facilities. Noninvasive hospitals hospitals without
on-site angiography  revascularization facilities. †Average household income (in Canadian dollars) was obtained from 1996
Canadian census data and corresponds to the Forward Sortation Area of the residents. ‡Among 7,648 bypass surgery (98.4% of
the total patients receiving bypass surgery). §Canadian Cardiovascular Society classes I–IV, A, B, C as described elsewhere (14).
High-risk coronary anatomy  left main stenosis, 3-vessel disease (with or without proximal LAD stenosis), or 2-vessel disease
with proximal LAD stenosis. ¶One vessel disease (with or without proximal LAD stenosis) or two vessel disease without
proximal LAD stenosis. #Length of hospital stay during the index admission includes in-hospital transfers and applies to all
15,166 AMI patients in the cohort. **Medication use at 90-days following discharge from the index AMI admission and applies
to patients 65 years of age and older.
ACE  angiotensin-converting enzyme; LAD  left anterior descending; AMI  acute myocardial infarction.
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patient and physician factors, hospitals with on-site revas-
cularization facilities still showed a 62.1% relative decrease
in the adjusted number of mean days waiting for revascu-
larization (p  0.001).
Shorter waiting times occurred in part because of a higher
prevalence of in-hospital procedures, particularly angio-
plasty, performed during the index AMI admission (adjust-
ed OR: 2.00; 95% CI: 1.76 to 2.28, p  0.001). Also, when
Table 2. The Relationship Between Baseline Characteristics and the Odds Ratio ( 95%
Confidence Interval) of Receiving CABG (vs. PTCA) Among Patients Hospitalized With AMI
at Invasive and Non-Invasive Institutions Between 1994 and 1998
Variables
Invasive Hospital
(n  2,198)
Non-Invasive Hospitals
(n  12,968)
Patient factors
Demographic
Youngest (20–49 yrs old) vs. others 0.47 (0.36–0.60) 0.41 (0.37–0.46)
Oldest (75 yrs old) vs. others 1.11 (0.87–1.43) 1.42 (1.26–1.61)
Female gender (%) 0.67 (0.55–0.82) 0.80 (0.74–0.86)
Lowest socioeconomic quintile vs.
others†
1.00 (0.81–1.24) 1.00 (0.92–1.09)
Highest socioeconomic quintile vs.
others†
0.61 (0.49–0.76) 0.90 (0.83–0.99)
Clinical status at admission
Lowest risk quartile‡ vs. others 0.54 (0.43–0.67) 0.53 (0.49–0.58)
Highest risk quartile‡ vs. others 1.59 (1.31–1.93) 1.69 (1.56–1.83)
*Invasive hospitals  hospitals with on-site angiography  revascularization facilities. Non-invasive hospitals  hospitals
without on-site angiography  revascularization facilities. †Average household income (in Canadian dollars) was obtained from
1996 Canadian census data and corresponds to the Forward Sortation Area of the residents. ‡Risk quartile is derived using the
clinical variables derived from the Ontario Myocardial Infarction mortality prediction rule. They include: congestive heart failure,
cardiogenic shock, pulmonary edema, arrythmias, diabetes with complications, stroke, malignancy, acute renal failure, chronic
renal failure (13).
AMI  acute myocardial infarction; CABG  coronary artery bypass graft; PTCA  percutaneous transluminal coronary
angioplasty.
Table 3. Waiting Times of Patients Revascularized Within One Year After AMI for Patients Hospitalized at Invasive Versus Non-
Invasive Institutions Between 1994 and 1998*
Variables Invasive
Hospitals
Non-Invasive
Hospitals p ValueWaiting Times
Angioplasty
The percentage (risk ratio) of angioplasty performed during the index
hospitalization vs. after discharge
70.6/29.4 (2.40) 40.5/59.5 (0.68)  0.001
Mean (median) number of days waiting in-hospital for angioplasty 6.1 (5) 11.9 (11)  0.001
Mean (median) number of days waiting for angioplasty after hospital
discharge
102.9 (73.0) 114.0 (96.5)  0.001
Mean (median) number of days between AMI and angioplasty 37.0 (8) 77.4 (31)  0.001
Bypass surgery
The percentage (risk ratio) of bypass surgery performed during the
index hospitalization vs. after discharge
45.6/54.4 (0.84) 31.1/68.9 (0.45)  0.001
The proportion of patients receiving bypass surgery within the
recommended maximum waiting times†
59.2 53.1  0.001
Mean (median) number of days waiting in-hospital for bypass surgery 10.0 (9) 16.2 (15)  0.001
Mean (median) number of days waiting for any revascularization after
hospital discharge
112.6 (89) 129.2 (112)  0.001
Mean (median) number of days waiting between AMI and any
revascularization
51.8 (12) 93.4 (48)  0.001
Any revascularization
The percentage (risk ratio) of revascularization performed during the
index hospitalization vs. after discharge
60.8/39.2 (1.55) 35.6/64.4 (0.55)  0.001
Mean (median) number of days waiting in-hospital for any
revascularization
7.3 (6) 13.9 (13)  0.001
Mean (median) number of days waiting for any revascularization after
hospital discharge
112.6 (89) 129.2 (112)  0.001
Mean (median) number of days waiting between AMI and any
revascularization
51.8 (12) 93.4 (48)  0.001
*Invasive hospitals  hospitals with on-site angiography  revascularization facilities. Non-invasive hospitals  hospitals without on-site angiography  revascularization
facilities. †As derived using clinical data obtained from the Ontario coronary artery bypass surgery triage registry.
AMI  acute myocardial infarction.
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patients admitted to non-invasive institutions were slated
for a procedure on the index admission, they waited for
transfers to invasive institutions (Table 3).
Adverse outcomes before revascularization. Among the
4,077 patients (44.3% of the eligible cohort) urgently
re-admitted to hospital before revascularization, 1,075
(26.4%) had already received coronary angiography after
their AMI. The median time interval between a cardiac
re-admission and revascularization was 18 days. As illus-
trated in Table 4, patients discharged from invasive hospi-
tals before their revascularization procedures experienced
fewer adverse cardiac events (41.5% vs. 68.9%, p  0.001)
and fewer days in-hospital (379 per 100 patients vs. 517 per
100 patients, p  0.001) than those discharged from
non-invasive institutions. An admission to an invasive
hospital was associated with a 30% reduction in the risk of
urgent cardiac re-admissions before revascularization (ad-
justed relative risk [RR] for invasive hospitals: 0.70, 95%
CI: 0.62 to 0.80, p  0.001) (Figs. 2 and 3). Subgroup
analysis demonstrated similar outcome benefits across age
strata and independent of the use of outpatient evidence-
based pharmacotherapies such as beta-blockers, aspirin,
ACE inhibitors, and statins (Fig. 3).
Adverse outcomes after revascularization. Once patients
had received their revascularization procedures, outcomes
were similar between invasive and non-invasive hospitals
(Table 4). Although post-procedural crude re-infarction
rates were marginally higher at invasive hospitals (3.4% vs.
2.4%, p  0.006), there were no significant differences after
adjusting for baseline clinical factors (adjusted RR: 1.18;
95% CI: 0.91 to 1.54, p  0.22). Inter-hospital group
similarities in post-procedural non-fatal outcomes were not
only independent of baseline characteristics (Fig. 2) but also
similar after adjusting for variations in the use evidence-
based outpatient pharmacotherapies (Fig. 3).
Given that all revascularized patients were followed up
for one year beginning from their initial AMI presentation,
longer outpatient waiting times would have directly resulted
in shortened exposure times to the risk of adverse events
beyond revascularization (median exposure periods to the
risk of events after procedures were 342 days per 100
patients vs. 275 days per 100 patients at invasive vs.
non-invasive hospitals, p  0.001). Accordingly, these
analyses were repeated among a subgroup of patients with
similar post-procedural exposure periods by confining the
sample to those who underwent revascularization during the
initial AMI admission. Our results were similar. Outcomes
after revascularization did not significantly vary between the
two hospital groups (adjusted RR for invasive hospitals:
0.88, 95% CI: 0.75 to 1.04, p  0.14).
Among patients revascularized during the index hospital-
ization, crude and adjusted one-year mortality rates were
equivalent between institution types (crude one-year mor-
tality rates at invasive and non-invasive hospitals: 5.8% and
5.3% respectively, p  0.41; adjusted RR for invasive
hospitals: 1.03, 95% CI: 0.79 to 1.35, p  0.81).
Table 4. Outcomes of Patients Revascularized Within One Year After AMI at Invasive Versus Non-Invasive Institutions Between
1994 and 1998
Variables
Adverse Outcomes
Invasive
Hospitals
Non-Invasive
Hospitals p Value
Before revascularization†
At least one recurrent cardiac admission per 100 AMI patients 31.7 45.6  0.001
MI readmissions rate per 100 AMI patients 5.8 11.6  0.001
Angina re-admission rate per 100 AMI patients 6.9 20.6  0.001
CHF re-admission rate per 100 AMI patients 1.5 2.3 0.02
The total number of recurrent cardiac admissions per 100 AMI patients 41.5 68.9  0.001
Hospital bed-days due to recurrent cardiac admissions per 100 AMI patients 379 517  0.001
After revascularization‡
At least one recurrent cardiac admission per 100 AMI patients 12.5 12.8 0.72
MI re-admission rate per 100 AMI patients 3.4 2.4 0.006
Angina re-admission rate per 100 AMI patients 7.6 8.1 0.49
CHF re-admission rate per 100 AMI patients 3.0 3.4 0.32
The total number of recurrent cardiac admissions per 100 AMI patients 20.7 18.8 0.56
Hospital bed-days due to recurrent cardiac admissions per 100 AMI patients 128 113 0.27
At any time§
At least one recurrent cardiac admission per 100 AMI patients 22.9 37.5  0.001
MI re-admission rate per 100 AMI patients 8.6 13.6  0.001
Angina re-admission rate per 100 AMI patients 13.8 26.3  0.001
CHF re-admission rate per 100 AMI patients 4.1 5.2 0.03
The total number of recurrent cardiac admissions per 100 AMI patients 35.9 62.8  0.001
Hospital bed-days due to recurrent cardiac admissions per 100 AMI patients 274 445  0.001
Cumulative number of days in-hospital for any reason (including the index
AMI) per 100 AMI patients
2,103 2,487  0.001
*Invasive hospitals  hospitals with on-site angiography  revascularization facilities. Non-invasive hospitals  hospitals without on-site angiography  revascularization
facilities. †Adverse events (urgent cardiac readmissions) before the revascularization procedure among patients discharged alive from the index AMI admission. ‡Adverse events
(urgent cardiac readmissions) after revascularization (during the first year after AMI) among patients discharged alive from hospital. §Any adverse event before or after the index
AMI admission.
AMI  acute myocardial infarction; CHF  congestive heart failure.
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Cumulative adverse outcomes (before or after revascular-
ization). In total, when ignoring the timing of revascular-
ization, invasive hospitals were associated with a 36%
reduction in the risk of death or recurrent cardiac admission
(Adjusted RR for invasive hospitals: 0.64, 95% CI: 0.59 to
0.70, p  0.001). Fewer hospitalizations resulted in an
average 384 fewer days in-hospital per 100 patients over
the first year of the AMI (Table 4). After adjusting for all
other factors, revascularization when performed during the
index AMI admission was associated with a 65.9% reduc-
tion in the risk of death or recurrent hospitalization (p 
0.001).
DISCUSSION
Among Ontario patients receiving revascularization after
AMI, those admitted to hospitals with on-site revascular-
ization facilities were preferentially referred to angioplasty,
whereas patients admitted to hospitals without on-site
revascularization facilities were more likely to receive bypass
surgery. Given that the vast majority of patients who were
initially admitted to invasive hospitals were able to receive
their angioplasty procedure during the index AMI admis-
sion, overall revascularization waiting times were, on aver-
age, 62.1% shorter at hospitals with on-site revasculariza-
Figure 2. Cumulative risk of adverse events before and after revascularization. Adverse events are defined as the recurrent cardiac hospitalization (first
recurrent admission for angina, myocardial infarction, or congestive heart failure).
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tion capacity than those without. The observed differences
were associated with a 36% decrease in the adjusted risk of
cardiac re-admissions after AMI—a difference largely at-
tributable to two factors: 1) fewer patients in the outpatient
queue originating from invasive hospitals because of earlier
interventions performed during the index AMI hospitaliza-
tion; and 2) a lower event rate in the outpatient queue
among those few patients discharged from invasive hospitals
who had yet to receive their revascularization during the
index admission. Differences in pre-procedural re-
admissions resulted in significantly fewer patient days in
hospital and probably lower hospital expenditures as a
result. Conversely, there were no significant outcome dif-
ferences between the two hospital groups once revascular-
ization had been performed.
Revascularization modality and on-site procedural ca-
pacity. Our results are consistent with other interventional
studies that have demonstrated a positive relationship be-
tween utilization rates of catheter-based invasive cardiac
procedures and on-site revascularization capacity after AMI
(1,20). To our knowledge, however, this is the first study to
demonstrate that such institutional factors also influence the
choice of which revascularization modality is undertaken
after AMI. Inter-hospital group differences in the revascu-
larization modality of choice were predominantly driven by
the angioplasty preferences of cardiologists practicing
within invasive compared with non-invasive hospitals. This
result is consistent with limited available evidence, which
demonstrates that referral rates for invasive cardiac proce-
dures do vary according to cardiology subspecialty (invasive
vs. non-invasive cardiologists) (10).
Early versus delayed interventions and outcomes. Avail-
able evidence from clinical trials has demonstrated similar
efficacies between angioplasty and bypass surgery after
revascularization (18). Indeed, early revascularization, not
modality, best explained the non-fatal outcome advantages
associated with invasive tertiary hospitals after AMI in our
study. Our results therefore highlight the importance of
timely intervention as an independent predictor of outcomes
after AMI (5). Facilitated access to angioplasty benefited
the majority of patients admitted to invasive hospitals by
allowing physicians to intervene early during the index AMI
hospitalization. Fewer downstream events among those who
had not yet undergone revascularization during the index
AMI admission suggest that physicians had already selected
higher-risk patients for intervention, leaving those at lower
risk of adverse events for discharge on medical therapy
alone.
Although it is possible that variations in the use of other
factors (e.g., intensity of outpatient follow-up or cardiac
rehabilitation services) may have partly accounted for the
outcome differences observed between invasive and non-
Figure 3. Adjusted risk of recurrent cardiac admissions at invasive (vs. non-invasive) hospitals. All models have been adjusted for sociodemographic
characteristics, clinical severity, attending physician specialty, and hospital academic affiliation, using Cox proportional hazards. These models adjusted for
variations in the use of medical therapies and pertain to patients 65 years of age and older. Medications include the use of aspirin, beta-blockers,
angiotensin-converting enzyme inhibitors, HMG-CoA reductase inhibitors, and the absence of calcium-channel blockers at hospital discharge.
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invasive centers in our study (21), we believe the relationship
between procedural waiting times and outcomes is compel-
ling for several reasons. First, this study included only those
patients selected for revascularization. Second, the short-
term outcome advantages associated with invasive hospitals
existed only during the interval of time in which patients
were awaiting revascularization. Conversely, no significant
outcome benefits associated with invasive hospitals were
apparent beyond revascularization. Third, the timeliness of
intervention itself was a predictor of outcome. Finally,
neither other proxies for better process of care (e.g., hospi-
tals’ academic affiliations) nor the use of evidence-based
pharmacotherapy could account for the outcome differences
between invasive and non-invasive hospitals in our study.
Many studies examining the outcome advantages associ-
ated with early aggressive interventions after AMI have
yielded inconsistent results (1,4,8,22,23). For example, in
one recent Swedish study, Stenestrand and Wallentin (8)
demonstrated that early revascularization (compared with
delayed conservative strategies) was associated with a 50%
RR reduction for mortality at one-year after AMI at
hospitals with both low and high revascularization volume
strategies. Yet, more recently, a study examining 25,515
U.S. patients enrolled in the Global Use of Streptokinase
and tPA (alteplase) for Occluded coronary arteries
(GUSTO)-I trial demonstrated no mortality benefits asso-
ciated with on-site revascularization (22). The advantages
for invasive hospitals seen in our study may therefore
specifically reflect the effects of long waiting times for
revascularization when patients are admitted with AMI to
non-invasive hospitals in Canada.
More specifically, studies designed to compare early
aggressive versus delayed conservative strategies have in
essence compared two process factors simultaneously:
higher versus lower utilization and early versus delayed
intervention. We took as given a rate of intervention after
AMI that would be judged moderate by international
standards, confined our analysis to those who actually
received revascularization, and therefore, focused in on only
one process factor—facilitated versus delayed access to
intervention. As a corollary, the baseline risk of adverse
outcomes diminishes exponentially in the days and weeks
that follow initial presentation with an acute coronary
syndrome (1). Thus, as patients are followed up over time
and stabilize, the initial risk and related differences in event
rates is washed out. In our study, the median revasculariza-
tion waiting time for patients admitted to non-invasive
community hospitals in Ontario was 48 days, a significantly
longer median waiting time than that experienced for most
patients who are referred for revascularization in the U.S.
(24).
Our results suggest that policy makers and system man-
agers must devise ways to facilitate revascularization in a
timely fashion for heart attack patients admitted to hospitals
without on-site revascularization capacity. Although event
rates for patients awaiting coronary angiography and bypass
surgery in Ontario are low, especially for patients who are
prioritized appropriately according to clinical urgency
(25,26) our study suggests that patients with recent AMI are
a particularly high-risk subgroup. Accordingly, policy mak-
ers must improve the efficiency of hospital transfers in order
to revascularize a greater number of potentially vulnerable
patients during the index AMI hospitalization.
Study limitations. There are limitations to our study. First,
we used a surrogate measure of waiting times. However, it
is a defensible and consistent surrogate. Recent evidence
suggests that the time interval between presentation of acute
coronary syndromes and revascularization is an important
independent prognostic measure of outcomes (5,7,8). Sec-
ond, not all patients who suffered adverse events may have
been waiting for a procedure; instead, the adverse event
itself may have triggered referral for a procedure. Nonethe-
less, our results similarly applied to the subgroup of patients
who had already received angiography and who were likely
therefore to be in the revascularization queue. Third, we had
limited data on clinical characteristics of patients undergo-
ing angioplasty. However, we did examine the symptom
status and anatomic characteristics of those patients receiv-
ing bypass surgery and found that such factors were distrib-
uted in similar proportions between invasive and non-
invasive institutions. Furthermore, with few exceptions, the
case-mix distribution of patients undergoing angioplasty
versus bypass surgery was similar between institution
groups. Thus, it is unlikely that additional clinical detail
would have accounted for the observed differences in selec-
tion, waiting times, and outcomes. Moreover, our sample
included all patients receiving revascularization after AMI
in Ontario and therefore is highly representative of the
Canadian population.
Conclusions. Our findings suggest that institutional char-
acteristics (i.e., on-site procedural capacity) are important in
determining the modality and timing of revascularization
after AMI. Delays in revascularization for patients with
AMI admitted to hospitals without on-site revascularization
facilities are associated with a higher risk of adverse events
and lengthier hospitalizations. Policy makers and clinicians
should ensure timely access for patients awaiting revascu-
larization after AMI to minimize adverse outcomes before
surgery or angioplasty.
Reprint requests and correspondence: Dr. David A. Alter,
Institute for Clinical Evaluative Sciences, G106-2075 Bayview
Avenue, Toronto, Ontario M4N 3M5, Canada. E-mail:
david.alter@ices.on.ca.
REFERENCES
1. Alter DA, Naylor CD, Austin PC, Tu JV. Long-term MI outcomes
at hospitals with or without on-site revascularization. JAMA 2001;
285:2101–8.
2. Chapple A, Gatrell A. Variations in use of cardiac services in England:
perceptions of general practitioners, general physicians and cardiolo-
gists. J Health Serv Res Policy 1998;3:153–8.
418 Alter et al. JACC Vol. 42, No. 3, 2003
Waiting Times, Revascularization, and Outcomes August 6, 2003:410–9
3. Llevadot J, Giugliano RP, Antman EM, et al. Availability of on-site
catheterization and clinical outcomes in patients receiving fibrinolysis
for ST-elevation myocardial infarction. Eur Heart J 2001;22:2104–15.
4. Feit F, Mueller HS, Braunwald E, et al. Thrombolysis In Myocardial
Infarction (TIMI) phase II trial: outcome comparison of a “conserva-
tive strategy” in community versus tertiary hospitals. The TIMI
Research Group. J Am Coll Cardiol 1990;16:1529–34.
5. FRagmin and Fast Revascularisation during InStability in Coronary
artery disease Investigators. Invasive compared with noninvasive treat-
ment in unstable coronary-artery disease: FRISC II prospective ran-
domised multicentre study. Lancet 1999;354:708–15.
6. Holmes DRJ. Acute coronary syndromes: extending medical interven-
tion for five days before proceeding to revascularization. Am J Cardiol
2000;86:36M–41M.
7. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of
early invasive and conservative strategies in patients with unstable
coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor
tirofiban. N Engl J Med 2001;344:1879–87.
8. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival
in 14-day survivors of acute myocardial infarction: a prospective cohort
study. Lancet 2002;359:1805–11.
9. White HD. Optimal treatment of patients with acute coronary
syndromes and non–ST-elevation myocardial infarction. Am Heart J
1999;138:S105–14.
10. Di Salvo TT, Paul SD, Lloyd-Jones D, et al. Care of acute myocardial
infarction by noninvasive and invasive cardiologists: procedure use,
cost and outcome. J Am Coll Cardiol 1996;27:262–9.
11. Chester M, Chen L, Kaski JC. Identification of patients at high risk
for adverse coronary events while awaiting routine coronary angio-
plasty. Br Heart J 1995;73:216–22.
12. Cardiac Care Network of Ontario. Target Setting Working Group.
Final Report and Recommendations. October 2000.
13. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM.
Development and validation of the Ontario acute myocardial infarc-
tion mortality prediction rules. J Am Coll Cardiol 2001;37:992–7.
14. Alter DA, Austin P, Tu JV. Use of coronary angiography, angioplasty
and bypass surgery after acute myocardial infarction in Ontario. In:
Naylor CD, Slaughter PM, editors. Cardiovascular Health and Ser-
vices in Ontario: An ICES Atlas. Toronto: Institute for Clinical
Evaluative Sciences, 1999:141–64.
15. Naylor CD, Sykora K, Jaglal SB, Jefferson S. Waiting for coronary
artery bypass surgery: population-based study of 8,517 consecutive
patients in Ontario, Canada. The Steering Committee of the Adult
Cardiac Care Network of Ontario. Lancet 1995;346:1605–9.
16. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic
status on access to invasive cardiac procedures and on mortality after
acute myocardial infarction. N Engl J Med 1999;341:1359–67.
17. Johansen H, Nair C, Luling M, Wolfson M. Revascularization and
heart attack outcomes. Health Rep 2002;13:35–46.
18. The Bypass Angioplasty Revascularization Investigation (BARI) In-
vestigators. Comparison of coronary bypass surgery with angioplasty in
patients with multivessel disease. N Engl J Med 1996;335:217–25.
19. Snijders TAB, Boster RJ. Multilevel Analysis: An Introduction to
Basic and Advanced Multilevel Modeling. London: Sage Publications,
1999.
20. Blustein J. High-technology cardiac procedures. The impact of service
availability on service use in New York State. JAMA 1993;270:344–9.
21. Mark DB, Naylor CD, Hlatky MA, et al. Use of medical resources and
quality of life after acute myocardial infarction in Canada and the
United States. N Engl J Med 1994;331:1130–5.
22. Mehta RH, Criger DA, Granger CB, et al. Patient outcomes after
fibrinolytic therapy for acute myocardial infarction at hospitals with
and without coronary revascularization capability. J Am Coll Cardiol
2002;40:1034–40.
23. Batchelor WB, Peterson ED, Mark DB, et al. A comparison of U.S.
and Canadian cardiac catheterization practices in detecting severe
coronary artery disease after myocardial infarction: efficiency, yield and
long-term implications. J Am Coll Cardiol 1999;34:12–9.
24. Carroll RJ, Horn SD, Soderfeldt B, James BC, Malmberg L. Inter-
national comparison of waiting times for selected cardiovascular
procedures. J Am Coll Cardiol 1995;25:557–63.
25. Maziak DE, Rao V, Christakis GT, et al. Can patients with left main
stenosis wait for coronary artery bypass grafting? Ann Thorac Surg
1996;61:552–7.
26. Natarajan MK, Mehta SR, Holder DH, et al. The risks of waiting for
cardiac catheterization: a prospective study. CMAJ 2002;167:1233–40.
419JACC Vol. 42, No. 3, 2003 Alter et al.
August 6, 2003:410–9 Waiting Times, Revascularization, and Outcomes
